Clin Infect Dis by Cope, Jennifer R. et al.
Use of the Novel Therapeutic Agent Miltefosine for the 
Treatment of Primary Amebic Meningoencephalitis: Report of 
One Fatal and One Surviving Case
Jennifer R. Cope, MD, MPH,
Centers for Disease Control and Prevention, Atlanta, GA, USA
Dennis A. Conrad, MD,
University of Texas Health Science Center, San Antonio, TX, USA
Naiomi Cohen, MD,
Miami Children’s Hospital, Miami, FL, USA
Manuel Cotilla, MD,
Miami Children’s Hospital, Miami, FL, USA
Alexandre DaSilva, PhD,
U.S. Food and Drug Administration, Laurel, MD, and Centers for Disease Control and Prevention, 
Atlanta, GA, USA
Jonathan Jackson, and
Centers for Disease Control and Prevention, Atlanta, GA, USA
Govinda Visvesvara, PhD
Centers for Disease Control and Prevention, Atlanta, GA, USA
Abstract
Primary amebic meningoencephalitis (PAM) is a fulminant central nervous system infection 
caused by the thermophilic free-living ameba Naegleria fowleri. Few survivals have been 
documented and adequate treatment is lacking. We report two PAM cases, one fatal and one 
surviving, treated with the novel antiparasitic agent miltefosine.
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Primary amebic meningoencephalitis (PAM) is a fulminant central nervous system infection 
caused by the thermophilic free-living ameba Naegleria fowleri. The infection occurs when 
freshwater containing the ameba enters the nose, crosses the cribriform plate, and enters the 
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brain. PAM is often clinically indistinguishable from bacterial meningitis, with early 
symptoms of headache, fever, nausea, and vomiting progressing rapidly to altered mental 
status, seizures, coma, and death [1]. Despite the availability of several antimicrobial agents 
that show in vitro activity against Naegleria fowleri, use of these agents clinically, even 
when administered early in the course of illness, has resulted in few survivors. Amphotericin 
B has been the mainstay of PAM treatment and all of the well-documented survivors have 
received it as part of their treatment regimen [2–5]. The antiparasitic agent miltefosine has 
shown some promise for the treatment of free-living ameba infections [6].
Case report 1
A 12-year-old male presented to a local community hospital on August 7, 2013 with a one-
day history of headaches, weakness, vomiting, fevers (39.4 °C), and altered mental status. 
The patient lived in a wooded area of central Florida where, on August 5, he was riding on a 
kneeboard pulled by an all-terrain vehicle with friends in a 2–3 foot deep ditch filled with 
stagnant rainwater. While participating in this activity, his head was, at times, completely 
submerged underwater. Lumbar puncture was performed with an opening pressure of 50 cm 
H2O (normal 10–20 cm H2O). Cerebrospinal fluid was noted to be cloudy with a white 
blood cell (WBC) count of 10,216 cells/μL, a red blood cell (RBC) count of 3,500 cells/μL, 
protein 560 mg/dL, and glucose <20 mg/dL. Computed tomography (CT) of the head 
without contrast was normal. Broad antimicrobial coverage was started and included 
acyclovir, liposomal amphotericin B, fluconazole, rifampin, vancomycin, and ceftriaxone. 
The following day, the patient’s neurologic status deteriorated. In consultation with the 
Centers for Disease Control and Prevention (CDC), the treatment regimen was tailored to 
include deoxycholate amphotericin B intravenously, fluconazole, azithromycin, and 
rifampin. Miltefosine was added once it arrived approximately 31 hours after his initial 
presentation. The diagnosis of PAM was confirmed with the identification of Naegleria 
fowleri in the CSF by polymerase chain reaction (PCR) testing at CDC, at which time a 
lumbar drain was placed and intrathecal amphotericin B was added. A follow-up CT 
demonstrated cerebral edema which was managed with hypertonic saline, mannitol, surgical 
decompression, and therapeutic hypothermia with no clinical improvement. Subsequent 
imaging showed brain herniation and the patient was declared brain dead on hospital day 16.
Case report 2
On August 17, 2013, an 8-year-old Hispanic male presented to a Texas hospital with a five 
day history of fever, headache, chills, nausea, and vomiting progressing to photophobia and 
altered mental status. The patient’s mother had sought medical care at three clinics in 
Mexico prior to seeking care in the United States. The patient had been spending the 
summer with his mother, who lived in an informal settlement adjacent to the Rio Grande. 
This settlement had no potable public water supply or sanitary sewer system; water for 
consumption was purchased in Texas, whereas water used for bathing and cleaning was 
obtained by direct piping of surface water from the Rio Grande. The patient enjoyed 
“splashing in the shallows” at the edge of the river. CSF appeared cloudy with a RBC count 
of 1,000 cells/μL, a WBC count of 2,312 cells/μL with 92% neutrophils, and protein 311 
mg/dL. The glucose concentration could not be determined accurately. When the CSF Gram 
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stain did not show any organisms, a Wright stain was performed revealing amebic 
trophozoites.
With a Glasgow Coma Score of 3, the patient was intubated and mechanically ventilated. A 
right frontal external ventricular drainage (EVD) catheter was placed in order to monitor 
intracranial pressure and provide therapeutic drainage as warranted. At the time of 
placement, the intraventricular pressure exceeded 40 mm Hg (normal 1–20 mm Hg). 
Treatment for PAM was promptly initiated and is summarized in Table 1. Miltefosine was 
requested from CDC and was administered 14 hours after the patient was admitted to the 
PICU. At the conclusion of his treatment course, he could react with healthcare providers 
only by withdrawal from noxious stimuli. He was able to breathe spontaneously, but did not 
have a consistent gag or cough reflex, nor could he evidence any coordinated ability for self-
care activities. After a 39-day hospital stay, the patient spent another 36 days on the 
pediatric rehabilitation service. He was discharged to home in the care of his family. 
Approximately eighteen months following discharge, the patient has static encephalopathy 
with profound persistent mental disability, seizure disorder partially controlled with 
anticonvulsant therapy, is non-verbal and cannot care for himself.
Discussion
These two PAM patients are notable in that they received the novel antiparasitic agent 
miltefosine as part of their treatment regimen. Miltefosine is an alkylphosphocholine 
compound that has predominantly been studied for the treatment of leishmaniasis [7]. Its 
antileishmanial and antiamebic mechanisms of action are unknown. The surviving patient 
reported here is the fifth case of well-documented survival in a PAM infection (Table 1). 
During the same summer in which these two PAM cases were diagnosed, a 12-year old 
adolescent female from Arkansas, USA was diagnosed with PAM and survived, making a 
full neurologic recovery [5]. Her treatment regimen included all of the drugs given to the 
two patients reported here. Notable differences in her clinical course and treatment from the 
two patients reported here included being treated with Naegleria-specific drugs 
approximately 48 hours after symptom onset and undergoing aggressive management of 
elevated intracranial pressure, including therapeutic hypothermia. In contrast, the 8-year-old 
Texas male survivor reported here had symptoms for five days before a PAM diagnosis was 
made and specific PAM therapy was initiated. While his elevated intracranial pressure was 
managed both medically and surgically, therapeutic hypothermia was not used in his case. 
The Florida child presented here did present early in the course of illness. However, some 
aspects of his care differed slightly from the Arkansas survivor, including having a lumbar 
drain placed (vs. EVD), receiving intrathecal amphotericin over two days after presentation 
to the hospital, and initially receiving liposomal amphotericin B (in vitro testing shows 
deoxycholate amphotericin B has lower MICs for Naegleria fowleri). However, it us 
unknown whether these small differences in care contributed to the varied outcomes of these 
three patients.
All three patients (the two reported here plus the Arkansas survivor) received miltefosine as 
part of their treatment regimen but with three very different outcomes: death, survival with 
poor neurologic outcome, and survival with full neurologic recovery. Therefore, while 
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miltefosine is a promising anti-Naegleria agent, it is not a magic bullet, and its 
administration does not assure recovery. Since 2013, when miltefosine became available 
through CDC, 100% (2/2) of surviving U.S. PAM cases received miltefosine compared with 
33% (3/9) of fatal U.S. PAM cases (CDC unpublished data). Surviving PAM, including 
survival with few or no deficits is likely multifactorial and includes early diagnosis and 
treatment, using combination drug therapy (including miltefosine), and aggressive 
management of elevated intracranial pressure based on the principles of traumatic brain 
injury [5].
Between 1962 and 2014, 133 cases of PAM were reported to CDC, with the majority 
occurring in southern-tier states in patients with recent exposure to warm freshwater lakes 
and rivers [1]. While the number of infections reported annually has remained stable (0–8), 
recent changes in the epidemiology of PAM are concerning. For the first time in 2010, a 
PAM case was reported from the northern state of Minnesota followed by additional cases 
from Minnesota, Indiana, and Kansas in 2011 and 2012, raising concerns about an 
expanding geographic range of illness caused by this thermophilic, potentially climate-
sensitive, pathogen [1]. In addition to exposure to recreational water, nasal exposure to tap 
water has now been associated with several PAM cases, including two patients who used tap 
water in a neti pot to irrigate their sinuses, one patient who used tap water to perform ritual 
ablution, and one patient who played on a backyard water slide supplied with tap water [8–
10]. Given these changes, clinicians in all regions of the United States should consider the 
diagnosis of PAM in a patient with meningitis and recent nasal freshwater exposure.
Clinicians who suspect PAM in a patient under their care should contact the CDC 
Emergency Operations Center (770-488-7100) for 24/7 diagnostic assistance, specimen 
collection guidance, and treatment recommendations, including the use of miltefosine. 
Confirmatory PCR testing is available at CDC with a turnaround time of 2–4 hours. 
Miltefosine is available directly from CDC under an expanded access investigational new 
drug (IND) protocol for treatment of free-living ameba infections in the United States [11]. 
With increased awareness of this deadly infection, prompt diagnosis and initiation of 
combination drug therapy, and aggressive management of elevated intracranial pressure, 
more patients might survive PAM. Clinicians are encouraged to report all suspected PAM 
cases to CDC, as each case provides valuable information for improving understanding of 
pathogenesis and treatment, regardless of outcome.
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